PRA Health Sciences selected by BARDA to be a member of its exclusive Clinical Studies Network
October 06 2020 - 4:02PM
PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today it has
been selected by the Biomedical Advanced Research and Development
Authority (BARDA) to be a member of its updated Clinical Studies
Network (CSN). Under a Clinical Trial Planning and Execution (CTPE)
contract award, PRA will serve as a valued partner that provides
clinical research services to develop medical countermeasures
(MCMs) that protect health and save lives in public health
emergencies.
“This program represents important research that is necessary to
protect and facilitate public health,” said Michael Massaro, Senior
Vice President, Project Delivery and Biometrics, PRA Health
Sciences. “We are proud to support BARDA’s Clinical Studies Network
where we can offer our clinical research experience, expertise, and
capabilities and be a healthcare intelligence partner for this
unique and urgent need.”
As part of the Office of the Assistant Secretary for
Preparedness and Response (ASPR) within the U.S. Department of
Health and Human Services (HHS), BARDA aids in securing the nation
from chemical, biological, radiological, and nuclear threats, as
well as pandemic influenza and emerging infectious diseases. BARDA
supports the advanced research, development and manufacturing of
MCMs, such as vaccines, drugs, and diagnostics. BARDA will leverage
the CSN to advance the development of MCMs by conducting rigorous
Phase I-IV clinical trials that assess the safety and efficacy of
drugs, devices, and biological products.
BARDA recently reconfigured the CSN contract to include the
Clinical Trial Planning and Execution contract as a multi-award
Indefinite Delivery/Indefinite Quantity contract over a five-year
period. During the term of their contract, PRA and other CSN CTPE
members can submit additional proposals for new work within the
project’s scope. This project has been funded in whole or in part
with federal funds from ASPR and BARDA, under Contract No.
75A50120D00019.
About PRA Health Sciences
PRA Health Sciences is one of the world’s leading global
contract research organizations by revenue, providing outsourced
clinical development and data solution services to the
biotechnology and pharmaceutical industries. PRA’s global clinical
development platform includes more than 75 offices across North
America, Europe, Asia, Latin America, Africa, Australia and the
Middle East and more than 17,500 employees worldwide. Since 2000,
PRA has participated in approximately 4,000 clinical trials
worldwide. In addition, PRA has participated in the pivotal or
supportive trials that led to U.S. Food and Drug Administration or
international regulatory approval of more than 95 drugs. To learn
more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES: Laurie Hurst, Sr. Director, Communications and
Public Relationshurstlaurie@prahs.com | +1 (919) 786-8435
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Sep 2024 to Oct 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Oct 2023 to Oct 2024